Suppression of lactation with lisuride

Area of Science:

• Endocrinology
• Pharmacology
• Reproductive Medicine

Background:

• Elevated prolactin (PRL) levels are common during the puerperium.
• Effective methods for lactation suppression are crucial for postpartum care.
• Ergot derivatives like bromocryptine are known for their PRL-lowering effects.

Purpose of the Study:

• To investigate the efficacy and safety of lisuride in managing postpartum prolactin levels.
• To compare lisuride's effect on prolactin and lactation with placebo and bromocryptine.
• To determine the dose-dependent effect of lisuride on prolactin secretion.

Main Methods:

• A clinical investigation involving postpartum women divided into treatment and control groups.
• Administration of varying doses of lisuride (100-900 micrograms) or placebo over 14 days.
• Measurement of prolactin (PRL) levels before and after treatment, and in response to suckling stimuli.

Main Results:

• Lisuride treatment (600 or 900 micrograms) significantly reduced elevated PRL levels in postpartum women.
• Clinical efficacy in preventing or suppressing lactation was observed and comparable to bromocryptine.
• Single oral doses of lisuride (200-300 micrograms) abolished postsuckling PRL increase, showing dose-dependent inhibition lasting over 8 hours.
• No severe side effects were reported with the tested lisuride dosages.

Conclusions:

• Lisuride is a clinically effective and safe option for lowering prolactin levels and suppressing lactation in the puerperium.
• Its efficacy is comparable to bromocryptine, offering a potential alternative treatment.
• Lisuride demonstrates a dose-dependent and long-lasting inhibition of prolactin secretion.